183 related articles for article (PubMed ID: 24376673)
1. Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma.
Bøgsted M; Bilgrau AE; Wardell CP; Bertsch U; Schmitz A; Bødker JS; Kjeldsen MK; Goldschmidt H; Morgan GJ; Dybkaer K; Johnsen HE
PLoS One; 2013; 8(12):e83252. PubMed ID: 24376673
[TBL] [Abstract][Full Text] [Related]
2. Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines.
Boegsted M; Holst JM; Fogd K; Falgreen S; Sørensen S; Schmitz A; Bukh A; Johnsen HE; Nyegaard M; Dybkaer K
PLoS One; 2011 Apr; 6(4):e19322. PubMed ID: 21559449
[TBL] [Abstract][Full Text] [Related]
3. Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma.
Laursen MB; Falgreen S; Bødker JS; Schmitz A; Kjeldsen MK; Sørensen S; Madsen J; El-Galaly TC; Bøgsted M; Dybkær K; Johnsen HE;
Exp Hematol; 2014 Nov; 42(11):927-38. PubMed ID: 25072621
[TBL] [Abstract][Full Text] [Related]
4. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
[TBL] [Abstract][Full Text] [Related]
5. A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
Gullà A; Di Martino MT; Gallo Cantafio ME; Morelli E; Amodio N; Botta C; Pitari MR; Lio SG; Britti D; Stamato MA; Hideshima T; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
Clin Cancer Res; 2016 Mar; 22(5):1222-33. PubMed ID: 26527748
[TBL] [Abstract][Full Text] [Related]
6. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.
Chen Q; Van der Sluis PC; Boulware D; Hazlehurst LA; Dalton WS
Blood; 2005 Jul; 106(2):698-705. PubMed ID: 15802532
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake.
Harada N; Nagasaki A; Hata H; Matsuzaki H; Matsuno F; Mitsuya H
Acta Haematol; 2000; 103(3):144-51. PubMed ID: 10940652
[TBL] [Abstract][Full Text] [Related]
9. Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells.
Zub KA; Sousa MM; Sarno A; Sharma A; Demirovic A; Rao S; Young C; Aas PA; Ericsson I; Sundan A; Jensen ON; Slupphaug G
PLoS One; 2015; 10(3):e0119857. PubMed ID: 25769101
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of the involvement of apurinic/apyrimidinic endonuclease 1 in the resistance to melphalan in multiple myeloma.
Xie J; Zhang L; Li M; Du J; Zhou L; Yang S; Zeng L; Li Z; Wang G; Wang D
BMC Cancer; 2014 Jan; 14():11. PubMed ID: 24400589
[TBL] [Abstract][Full Text] [Related]
11. c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB.
Greco C; D'Agnano I; Vitelli G; Vona R; Marino M; Mottolese M; Zuppi C; Capoluongo E; Ameglio F
Int J Immunopathol Pharmacol; 2006; 19(1):67-79. PubMed ID: 16569345
[TBL] [Abstract][Full Text] [Related]
12. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.
Damiano JS; Cress AE; Hazlehurst LA; Shtil AA; Dalton WS
Blood; 1999 Mar; 93(5):1658-67. PubMed ID: 10029595
[TBL] [Abstract][Full Text] [Related]
13. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Mateos MV; Cavo M; Blade J; Dimopoulos MA; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Krevvata M; Chen Y; Wang J; Kudva A; Ukropec J; Wroblewski S; Qi M; Kobos R; San-Miguel J
Lancet; 2020 Jan; 395(10218):132-141. PubMed ID: 31836199
[TBL] [Abstract][Full Text] [Related]
14. Evidence that aberrant protein metabolism contributes to chemoresistance in multiple myeloma cells.
Sipes RK; Xia X; Lewis BS; Burgis NE
Oncol Rep; 2012 Jun; 27(6):2031-8. PubMed ID: 22426518
[TBL] [Abstract][Full Text] [Related]
15. A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment.
Alagpulinsa DA; Yaccoby S; Ayyadevara S; Shmookler Reis RJ
Cancer Biol Ther; 2015; 16(6):976-86. PubMed ID: 25996477
[TBL] [Abstract][Full Text] [Related]
16. Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line.
Mutlu P; Ural AU; Gündüz U
Biomed Pharmacother; 2012 Apr; 66(3):228-31. PubMed ID: 22425183
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
18. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.
Sousa MM; Zub KA; Aas PA; Hanssen-Bauer A; Demirovic A; Sarno A; Tian E; Liabakk NB; Slupphaug G
PLoS One; 2013; 8(2):e55493. PubMed ID: 23405159
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
Buzzeo R; Enkemann S; Nimmanapalli R; Alsina M; Lichtenheld MG; Dalton WS; Beaupre DM
Clin Cancer Res; 2005 Aug; 11(16):6057-64. PubMed ID: 16115951
[TBL] [Abstract][Full Text] [Related]
20. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
